Abeona Therapeutics (ABEO) Gains from Investment Securities (2016 - 2026)

Abeona Therapeutics' Gains from Investment Securities history runs 6 years deep, the most recent figure standing at -$5.4 million for Q1 2026.

• In Q1 2026, Gains from Investment Securities rose 25.66% year-over-year to -$5.4 million; the TTM figure through Mar 2026 stood at -$4.3 million (up 82.01% YoY), while the FY2025 annual figure was -$6.1 million, down 913.11% from the prior year.
• Gains from Investment Securities for Q1 2026 stood at -$5.4 million, down from -$1.5 million in the prior quarter.
• The five-year high for Gains from Investment Securities was $17.3 million in Q1 2024, with the low at -$24.9 million in Q2 2024.
• The 5-year median for Gains from Investment Securities is -$2.3 million (2023), against an average of -$615176.5.
• Peak annual rise in Gains from Investment Securities reached 1276.57% in 2024, while the deepest fall reached 388.87% in 2024.
• Abeona Therapeutics' Gains from Investment Securities stood at -$5.4 million in 2022, then jumped by 178.51% to $4.2 million in 2023, then sank by 260.17% to -$6.8 million in 2024, then jumped by 77.54% to -$1.5 million in 2025, then tumbled by 253.88% to -$5.4 million in 2026.
• Business Quant data shows ABEO's Gains from Investment Securities at -$5.4 million in Q1 2026, -$1.5 million in Q4 2025, and -$2.8 million in Q3 2025.